Médica neurologista com fellowship em neuroimunologia pela Universidade de São Paulo (USP).
A Dra. Aline de Moura Brasil Matos atua como especialista em Esclerose Múltipla, Neuromielite Óptica, Encefalites Autoimunes e outras doenças inflamatórias do sistema nervoso, integrando o grupo Imuno Brasil.
Pesquisadora no centro de pesquisas clínicas CPClin/DASA e doutoranda no Instituto de Medicina Tropical de São Paulo/USP, realiza pesquisas em esclerose múltipla, encefalites autoimunes e manifestações neurológicas associadas a viroses emergentes.
Professora Universitária do Centro Universitário São Camilo-SP (curso de medicina), atuou como médica colaboradora do grupo de Doenças Desmielinizantes do Hospital das Clínicas FMUSP e grupo de Neurociências do Instituto de Infectologia Emílio Ribas.
Universidade Federal do Ceará
Medicina
Hospital Geral de Fortaleza
Neurologia
Universidade de São Paulo
Neuroimunologia
Universidade de São Paulo
Doutorado em Andamento
Academia Brasileira de Neurologia
Membro Titular
Encephalitis Society
Professional Member
Encephalitis Society
2019 International Seed Funding
Harvard P.H. Chan School of Public Health
2021 Outstanding Teaching Assistant Principles and Practice of Clinical Research
Centro Universitário São Camilo
Profa. Curso de Medicina 2022 – atual
Centro de Pesquisa Clínica DASA
Principal Investigator 2022 – atual
Universidade de São Paulo
Instituto de Medicina Tropical – LIM 52 – virologia
Doutoranda em Doenças Infecciosas e Parasitárias 2020-atual
Academia Brasileira de Neurologia
Departamento científico de Neuroepidemiologia
Secretária 2025 – atual
Universidade de São Paulo
Colaboradora
Ambulatório Neuroimunologia 2018-2023
Instituto de Infectologia Emílio Ribas
Colaboradora
Ambulatório Neuroinfectologia 2018-2022
Harvard P.H. Chan School of Public Health
Principles and Practice of Clinical Research
Teaching Assistant 2021-2021
Neurological syndromes associated with COVID-19: a multicenter study in Brazil. BMC INFECTIOUS DISEASES, v. 25, p. 123, 2025.
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease. Neurology-Neuroimmunology & Neuroinflammation, v. 12, p. 1, 2025.
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, v. 1, p. 1, 2024.
Immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination. JAMA neurology, v. 80, n. 9, p. 989-995, 2023.
Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. PloS one, v. 17, n. 6, p. e0263595, 2022.
Subacute Cognitive Impairment in Individuals With Mild and Moderate COVID-19: A Case Series. Frontiers in Neurology, v. 12, p. 1, 2021
The long road to learn the meaning of p-value in medical schools: challenges for a research methodology training in medical schools. PRINCIPLES AND PRATICE OF CLINICAL RESEARCH, v. 7, p. 46-50, 2021.
Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. PloS one, v. 17, n. 6, p. e0263595, 2022.
High proportion of Guillain-Barré syndrome associated with chikungunya in Northeast Brazil. Neurology-Neuroimmunology & Neuroinflammation, v. 7, p. e833, 2020.
Dichotomy in Fatal Outcomes in a Large Cohort of People Living with HTLV-1 in São Paulo, Brazil. PATHOGENS, v. 9, p. 25, 2020.
Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arquivos de Neuro-Psiquiatria (Online), v. 1, p. 1, 2020.